scholarly journals Combination treatment with an ETA-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models

2003 ◽  
Vol 18 (1) ◽  
pp. 62-69 ◽  
Author(s):  
S. R. Orth
Keyword(s):  
Combination Treatment ◽  
Ace Inhibitor ◽  
Receptor Blocker ◽  
Rat Models ◽  
Transplant Vasculopathy ◽  
Eta Receptor

scholarly journals Effects of Combination of ACE Inhibitor and Angiotensin Receptor Blocker on Cardiac Remodeling, Cardiac Function, and Survival in Rat Heart Failure

Circulation ◽  
2001 ◽  
Vol 103 (1) ◽  
pp. 148-154 ◽  
Author(s):  
Shokei Kim ◽  
Minoru Yoshiyama ◽  
Yasukatsu Izumi ◽  
Hitomi Kawano ◽  
Manabu Kimoto ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiac Function ◽  
Cardiac Remodeling ◽  
Rat Heart ◽  
Angiotensin Receptor Blocker ◽  
Ace Inhibitor ◽  
Receptor Blocker ◽  
Angiotensin Receptor

scholarly journals Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19

2020 ◽  
Vol 31 (9) ◽  
pp. 1941-1943 ◽  
Author(s):  
Jan Wysocki ◽  
Enrique Lores ◽  
Minghao Ye ◽  
Maria Jose Soler ◽  
Daniel Batlle
Keyword(s):  
Ace Inhibitor ◽  
Receptor Blocker ◽  
Ang Ii

scholarly journals Antihypertensive effects of a novel orally active angiotensin converting enzyme (ACE) inhibitor altiopril calcium (MC-838) in several hypertensive rat models

1989 ◽  
Vol 49 ◽  
pp. 214
Author(s):  
Junichiro Aono ◽  
Takaki Koga ◽  
Tamotsu Yamazaki ◽  
Yasuyuki Shiraki ◽  
Hiroyuki Nabata ◽  
...  
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Ace Inhibitor ◽  
Converting Enzyme ◽  
Rat Models ◽  
Hypertensive Rat ◽  
Orally Active

P18 Beta-blocker/ACE-inhibitor combination treatment in mdx mice

2012 ◽  
Vol 22 ◽  
pp. S12
Author(s):  
A. Blain ◽  
E. Greally ◽  
G. MacGowan ◽  
S. Laval ◽  
A. Blamire ◽  
...  
Keyword(s):  
Combination Treatment ◽  
Beta Blocker ◽  
Ace Inhibitor ◽  
Mdx Mice ◽  
Inhibitor Combination

Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats

2011 ◽  
Vol 300 (6) ◽  
pp. G1094-G1104 ◽  
Author(s):  
Kosuke Kaji ◽  
Hitoshi Yoshiji ◽  
Mitsuteru Kitade ◽  
Yasuhide Ikenaka ◽  
Ryuichi Noguchi ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Amino Acid ◽  
Angiotensin Ii ◽  
Liver Fibrosis ◽  
Combination Treatment ◽  
Iron Chelator ◽  
Receptor Blocker ◽  
Type I ◽  
Oral Iron Chelator

Angiotensin II type I receptor blocker and iron chelator reportedly exert suppressive effects on nonalcoholic steatohepatitis (NASH) progression, including liver fibrosis and hepatocarcinogenesis. The aim of this study was to elucidate the combined effect of losartan (LOS), an angiotensin II type I receptor blocker, and deferasirox (DSX), a newly developed oral iron chelator, on the progression of NASH in rats. To induce NASH, F344 rats were fed a choline-deficient l-amino acid-defined diet for 12 wk, and the effects of LOS and DSX at clinically comparable low doses were elucidated in conjunction with oxidative stress, neovascularization, and hepatic stellate cells (HSC) activation, all known to play important roles in the progression of NASH. Treatment with both LOS and DSX suppressed choline-deficient l-amino acid-defined diet-induced liver fibrosis development and hepatocarcinogenesis. This combination treatment exerted a stronger inhibitory effect compared with treatment with a single agent. These inhibitory effects occurred almost concurrently with the suppression of oxidative stress, neovascularization, and HSC activation. Our in vitro study demonstrated that LOS and DSX inhibited angiotensin II-induced proliferation, transforming growth factor-β1 expression of activated HSC, and in vitro angiogenesis. These results indicated that dual inhibition by combined treatment of LOS and DSX attenuated the progression of NASH. Since both agents are widely used in clinical practice, this combination therapy may represent a potential new strategy against NASH in the near future.

Sign in / Sign up

Export Citation Format

Share Document